Skip to main content

Table 5 PFS according to lines of treatment

From: Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit

 

Survivors < 4 years (n = 188)

Long-term survivors (≥ 4 years) (n = 60)

p value

 

n

PFS (months) (IQR)

n

PFS (months) (IQR)

 

1st-line overall

Median (interval) (months)

188

10.8 (0.7–46.6)

60

15.7 (3.5–69)

0.0001

Type of treatment

Chemotherapy plus bevacizumab

71

12 (1–46.6)

13

25.9 (11.6–69)

 

Chemotherapy plus anti-EGFR

7

16.1 (6.5–32)

1

5.1

Chemotherapy alone

110

10.1 (0.7–39.1)

46

13.1 (3.5–60.8)

2nd-line overall

Median (interval) (months)

154

4.4 (0.2–21.9)

51

9.8 (2.0–47.8)

< 0.001

Type of treatment

Chemotherapy plus bevacizumab

25

5.7 (1.3–19.4)

8

9.45 (2.1–24.3)

 

Chemotherapy plus anti-EGFR

28

3.05 (0.2–14.1)

5

10.3 (2.5–24.7)

Chemotherapy alone

101

4.3 (0.2–21.9)

38

9.65 (2–47.8)

3rd-line overall

Median (interval) (months)

103

3.2 (0.6–20.2)

43

7.6 (0.2–33)

< 0.001

Type of treatment

Chemotherapy plus bevacizumab

1

4.65 (2.6–6.7)

3

8 (7.3–16.2)

 

Chemotherapy plus anti-EGFR

33

3.45 (0.6–9.9)

17

8.1 (1.9–33)

Chemotherapy alone

69

3.1 (0.4–20.2)

23

7.1 (0.2–28)

4th-line overall

Median (interval) (months)

51

2.6 (0.6–8.8)

28

7.7 (2.2–17.9)

< 0.001

Type of treatment

Chemotherapy plus bevacizumab

0

–

1

12.1

 

Chemotherapy plus anti-EGFR

5

4.1 (2.6–8.8)

6

15.5 (8.2–17.9)

Chemotherapy alone

46

2.6 (0.6–7)

21

6.35 (2.2–17.1)